NCT02171143View on ClinicalTrials.gov

A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions

Rheumatoid ArthritisPharmacokinetics of ASP2409

Interventions

DRUG

ASP2409

intravenous (IV)

DRUG

Placebo

intravenous (IV)

Trial Locations (10)

16635

Altoona Center for Clinical Research, Duncansville

27612

Carolina Phase 1 Research, Raleigh

32132

Riverside Clinical Research, Edgewater

33765

Clinical Research of West Florida, Inc., Clearwater

36027

Pinnacle Research Group, LLC, Anniston

45255

Community Research, Cincinnati

73122

Lynn Health Science Institute, Oklahoma City

75231

Metroplex Clinical Research Center, LLC, Dallas

78217

Texas Arthritis Research Center, San Antonio

92626

West Coast Clinical Trials, LLC, Costa Mesa

All Listed Sponsors

lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT02171143 - A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate | Biotech Hunter | Biotech Hunter